KR20140129439A - Food composition for relieving muscle fatigue after exercise - Google Patents
Food composition for relieving muscle fatigue after exercise Download PDFInfo
- Publication number
- KR20140129439A KR20140129439A KR20130047344A KR20130047344A KR20140129439A KR 20140129439 A KR20140129439 A KR 20140129439A KR 20130047344 A KR20130047344 A KR 20130047344A KR 20130047344 A KR20130047344 A KR 20130047344A KR 20140129439 A KR20140129439 A KR 20140129439A
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- parts
- powder
- vitamin
- wph
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 235000013305 food Nutrition 0.000 title claims abstract description 22
- 206010049565 Muscle fatigue Diseases 0.000 title claims abstract description 12
- 239000000843 powder Substances 0.000 claims description 69
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 24
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 16
- 235000005979 Citrus limon Nutrition 0.000 claims description 15
- 244000131522 Citrus pyriformis Species 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 14
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 12
- 239000000796 flavoring agent Substances 0.000 claims description 12
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 12
- 229930091371 Fructose Natural products 0.000 claims description 11
- 239000005715 Fructose Substances 0.000 claims description 11
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 11
- 229940024606 amino acid Drugs 0.000 claims description 11
- 235000001014 amino acid Nutrition 0.000 claims description 11
- 150000001413 amino acids Chemical class 0.000 claims description 11
- 239000008103 glucose Substances 0.000 claims description 11
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 11
- 235000010755 mineral Nutrition 0.000 claims description 11
- 239000011707 mineral Substances 0.000 claims description 11
- 229940088594 vitamin Drugs 0.000 claims description 11
- 229930003231 vitamin Natural products 0.000 claims description 11
- 235000013343 vitamin Nutrition 0.000 claims description 11
- 239000011782 vitamin Substances 0.000 claims description 11
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 10
- 235000013325 dietary fiber Nutrition 0.000 claims description 10
- 235000019634 flavors Nutrition 0.000 claims description 10
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 10
- 235000015097 nutrients Nutrition 0.000 claims description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- 229920000858 Cyclodextrin Polymers 0.000 claims description 9
- 239000004386 Erythritol Substances 0.000 claims description 9
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 9
- 239000001116 FEMA 4028 Substances 0.000 claims description 9
- 235000010469 Glycine max Nutrition 0.000 claims description 9
- 229920002907 Guar gum Polymers 0.000 claims description 9
- 229960004543 anhydrous citric acid Drugs 0.000 claims description 9
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 9
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 9
- 229960004853 betadex Drugs 0.000 claims description 9
- 229940009714 erythritol Drugs 0.000 claims description 9
- 235000019414 erythritol Nutrition 0.000 claims description 9
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 9
- 239000000665 guar gum Substances 0.000 claims description 9
- 235000010417 guar gum Nutrition 0.000 claims description 9
- 229960002154 guar gum Drugs 0.000 claims description 9
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 claims description 8
- PVXPPJIGRGXGCY-DJHAAKORSA-N 6-O-alpha-D-glucopyranosyl-alpha-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](O)(CO)O1 PVXPPJIGRGXGCY-DJHAAKORSA-N 0.000 claims description 8
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Chemical compound OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 8
- 108010011485 Aspartame Proteins 0.000 claims description 8
- 102000002322 Egg Proteins Human genes 0.000 claims description 8
- 108010000912 Egg Proteins Proteins 0.000 claims description 8
- 244000068988 Glycine max Species 0.000 claims description 8
- 239000000605 aspartame Substances 0.000 claims description 8
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 8
- 235000010357 aspartame Nutrition 0.000 claims description 8
- 229960003438 aspartame Drugs 0.000 claims description 8
- 235000014103 egg white Nutrition 0.000 claims description 8
- 210000000969 egg white Anatomy 0.000 claims description 8
- 239000000377 silicon dioxide Substances 0.000 claims description 8
- 235000012239 silicon dioxide Nutrition 0.000 claims description 8
- 229930003779 Vitamin B12 Natural products 0.000 claims description 7
- 235000013399 edible fruits Nutrition 0.000 claims description 7
- -1 nicotinate amide Chemical class 0.000 claims description 7
- 235000020733 paullinia cupana extract Nutrition 0.000 claims description 7
- 235000019163 vitamin B12 Nutrition 0.000 claims description 7
- 239000011715 vitamin B12 Substances 0.000 claims description 7
- 239000004475 Arginine Substances 0.000 claims description 6
- 235000007542 Cichorium intybus Nutrition 0.000 claims description 6
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 6
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 6
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 6
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 6
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 6
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 6
- 229930003471 Vitamin B2 Natural products 0.000 claims description 6
- 229960003121 arginine Drugs 0.000 claims description 6
- 235000009697 arginine Nutrition 0.000 claims description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 6
- 229960001230 asparagine Drugs 0.000 claims description 6
- 235000009582 asparagine Nutrition 0.000 claims description 6
- 229960005261 aspartic acid Drugs 0.000 claims description 6
- 235000003704 aspartic acid Nutrition 0.000 claims description 6
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 6
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 6
- 229960002079 calcium pantothenate Drugs 0.000 claims description 6
- 229960000304 folic acid Drugs 0.000 claims description 6
- 235000019152 folic acid Nutrition 0.000 claims description 6
- 239000011724 folic acid Substances 0.000 claims description 6
- 235000004554 glutamine Nutrition 0.000 claims description 6
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 6
- 235000014705 isoleucine Nutrition 0.000 claims description 6
- 229960000310 isoleucine Drugs 0.000 claims description 6
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 6
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 6
- 239000001508 potassium citrate Substances 0.000 claims description 6
- 229960002635 potassium citrate Drugs 0.000 claims description 6
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 claims description 6
- 235000011082 potassium citrates Nutrition 0.000 claims description 6
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims description 6
- 229960002477 riboflavin Drugs 0.000 claims description 6
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 6
- 235000014393 valine Nutrition 0.000 claims description 6
- 229960004295 valine Drugs 0.000 claims description 6
- 239000004474 valine Substances 0.000 claims description 6
- 235000019164 vitamin B2 Nutrition 0.000 claims description 6
- 239000011716 vitamin B2 Substances 0.000 claims description 6
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 5
- 108010046377 Whey Proteins Proteins 0.000 claims description 5
- 102000007544 Whey Proteins Human genes 0.000 claims description 5
- 229960003767 alanine Drugs 0.000 claims description 5
- 235000004279 alanine Nutrition 0.000 claims description 5
- 239000004227 calcium gluconate Substances 0.000 claims description 5
- 229960004494 calcium gluconate Drugs 0.000 claims description 5
- 235000013927 calcium gluconate Nutrition 0.000 claims description 5
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims description 5
- 239000001527 calcium lactate Substances 0.000 claims description 5
- 229960002401 calcium lactate Drugs 0.000 claims description 5
- 235000011086 calcium lactate Nutrition 0.000 claims description 5
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims description 5
- 235000005772 leucine Nutrition 0.000 claims description 5
- 229960003136 leucine Drugs 0.000 claims description 5
- 239000003381 stabilizer Substances 0.000 claims description 5
- 235000021119 whey protein Nutrition 0.000 claims description 5
- 239000011787 zinc oxide Substances 0.000 claims description 5
- 241000723343 Cichorium Species 0.000 claims description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 4
- 239000013078 crystal Substances 0.000 claims description 4
- 235000003599 food sweetener Nutrition 0.000 claims description 4
- 239000000419 plant extract Substances 0.000 claims description 4
- 239000003531 protein hydrolysate Substances 0.000 claims description 4
- 239000003765 sweetening agent Substances 0.000 claims description 4
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 3
- 235000013361 beverage Nutrition 0.000 claims description 3
- 229960003390 magnesium sulfate Drugs 0.000 claims description 3
- 235000005152 nicotinamide Nutrition 0.000 claims description 3
- 239000011570 nicotinamide Substances 0.000 claims description 3
- 229960001296 zinc oxide Drugs 0.000 claims description 3
- 235000014692 zinc oxide Nutrition 0.000 claims description 3
- 239000001692 EU approved anti-caking agent Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 229960003966 nicotinamide Drugs 0.000 claims description 2
- 244000298479 Cichorium intybus Species 0.000 claims 2
- 230000000996 additive effect Effects 0.000 claims 2
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims 2
- 229960002743 glutamine Drugs 0.000 claims 2
- 239000011664 nicotinic acid Substances 0.000 claims 1
- 235000001968 nicotinic acid Nutrition 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 abstract description 36
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 abstract description 36
- 229910021529 ammonia Inorganic materials 0.000 abstract description 18
- 229960000890 hydrocortisone Drugs 0.000 abstract description 18
- 210000004369 blood Anatomy 0.000 abstract description 15
- 239000008280 blood Substances 0.000 abstract description 15
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 abstract description 11
- 239000000126 substance Substances 0.000 abstract description 7
- 239000013589 supplement Substances 0.000 abstract description 5
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 28
- 206010016256 fatigue Diseases 0.000 description 21
- 238000011084 recovery Methods 0.000 description 15
- 239000004310 lactic acid Substances 0.000 description 14
- 235000014655 lactic acid Nutrition 0.000 description 14
- 230000000694 effects Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 7
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000037406 food intake Effects 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 3
- 239000001905 cichorium intybus l. root extract Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000003792 electrolyte Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 229940107700 pyruvic acid Drugs 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 229930003270 Vitamin B Natural products 0.000 description 2
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 230000000386 athletic effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960004106 citric acid Drugs 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 229960003624 creatine Drugs 0.000 description 2
- 239000006046 creatine Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 238000003672 processing method Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- LXNHXLLTXMVWPM-UHFFFAOYSA-N Vitamin B6 Natural products CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000009956 central mechanism Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007958 cherry flavor Substances 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 229940108928 copper Drugs 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229960003284 iron Drugs 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229960001866 silicon dioxide Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000002438 stress hormone Substances 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/20—Synthetic spices, flavouring agents or condiments
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
본 발명은 운동 후 근육 피로 개선용 식품 조성물에 관한 것이다.
The present invention relates to a food composition for improving muscle fatigue after exercise.
운동 수행 능력을 향상시키는 데 도움을 주는 요인으로는 유전적인 소질, 트레이닝 방법, 스포츠 장비 및 운동 보조제 섭취 등이 있다(윤성진 등, 한국사회체육학회지, 47, pp855-866, 2012; 이명천 등, 라이프사이언스, pp17-19, 2012). 특히, 운동 보조제 섭취의 효과는 경기의 승·패 및 기록에 큰 영향을 미친다. 예를 들어, 글루코스와 전해질이 혼합된 용액이나, 탄수화물 및 전해질 음료와 같은 운동 보조제를 섭취하면 운동 지속시간이 연장된다. 또한, 운동 후반부의 혈중 글루코스 농도의 저하를 방지함으로써 운동지속시간을 증가시킬 수 있고(Sherman, W. M., Medicine and Science in Sports and Exercise, 21:598-604, 1989), 크레아틴을 투여하거나, 글루코스와 프럭토스가 혼합된 음료를 섭취함으로써 더욱 빠른 운동속도를 나타내기도 한다(Jeukendrup, A. E., Carbohydrate feeding during exercise, 8(2):77-86, 2008). 탄수화물과 크레아틴을 복합 섭취하면 무산소성 능력을 유의하게 증가시킬 수 있다(김재호 등, 한국체육교육학회지, 8(1), pp224-232, 2003). 이러한 배경에 힘입어 운동 보조제는 현재 대다수의 운동 선수가 섭취하고 있을 뿐만 아니라 일반인에게도 광범위하게 이용되고 있다.
The results of this study were as follows: 1) The factors that contribute to the improvement of exercise performance include genetic factors, training methods, sports equipment, and athletic supplements (Yun Sung Jin et al., Journal of Korean Society of Sports Medicine, 47, pp855-866, Science, pp17-19, 2012). In particular, the effect of exercise supplementation has a great influence on the win / loss and record of the game. For example, ingesting a solution of glucose and electrolyte or a supplement of exercise such as carbohydrates and electrolyte drinks may prolong exercise duration. In addition, it is possible to increase the duration of exercise by preventing lowering of the blood glucose concentration in the post-exercise period (Sherman, WM, Medicine and Science in Sports and Exercise , 21: 598-604, 1989), administering creatine, Fructose may also be able to achieve faster rates of exercise by ingesting mixed beverages (Jeukendrup, AE, Carbohydrate feeding during exercise, 8 (2): 77-86, 2008). The combination of carbohydrate and creatine can significantly increase anaerobic ability (Kim Jae-ho et al., Journal of Korean Physical Education, 8 (1), pp224-232, 2003). Because of this background, athletic supplements are currently being consumed by the majority of athletes as well as being widely used by the general public.
한편, 운동 중 발생하는 근육 피로의 주요 원인으로는 체내에 저장된 에너지의 부족, 신경 자극 전달의 어려움, 운동 시 근육 및 혈액에 생성되는 대사산물의 축적 등이 대표적인 요인으로 알려져 있다. 운동 시 생성되는 대산산물 중 젖산은 말초 피로요인 중 하나이며, 스포츠 현장에서 근육의 에너지원이나 피로의 정도를 파악하는 지표로 널리 활용되고 있다. 신체활동 중 산소공급이 충분하며 신속한 에너지 공급이 필요하지 않을 시에는 피루브산(Pyruvic acid; PA)이 TCA 회로로 들어가 CO2 및 물을 생성하면서 ATP를 공급하지만(임기원 등, 운동영양학회지, 5(2), pp1-12, 2001), ATP와 PA가 고갈되면, 젖산 시스템에 의해 에너지를 공급받게 되고 그 부산물로 젖산을 생성함으로써 근세포가 산성화되어 피로를 유발하게 된다. The main causes of muscle fatigue during exercise are lack of energy stored in the body, difficulty in transmitting nerve impulses, and accumulation of metabolic products in muscles and blood during exercise. Lactic acid, one of the major products produced during exercise, is one of the peripheral fatigue factors and widely used as an indicator of the energy source and fatigue level of muscles in sport scene. Pyruvic acid (PA) enters the TCA circuit to supply CO 2 and water while producing ATP, if the oxygen supply is sufficient during physical activity and rapid energy supply is not needed 2), pp1-12, 2001). When ATP and PA are depleted, energy is supplied by the lactic acid system, and lactic acid is produced as a byproduct of it, causing muscle cells to become acidic and cause fatigue.
암모니아도 운동 시 피로 상태를 잘 반영하는 것으로 알려져 있다. 암모니아의 중추적 피로 작용 기전은 독성을 가진 암모니아가 다량 축적될 시에는 기면상태, 경련, 운동실조, 혼수상태 등 운동기능에 장애를 나타내고, 말초적 피로 기전은 근육 내의 암모니아 축적이 근육의 통증 감지와 관련이 있는 구심성 신경을 자극할 수 있기 때문에 피로를 유발한다. Ammonia is also known to reflect fatigue conditions during exercise. The central mechanisms of fatigue in ammonia are the accumulation of toxic ammonia, which may impair the function of the locomotor system, including spasm, convulsions, ataxia, and coma. The peripheral fatigue mechanism is related to the accumulation of ammonia in the muscle Which can stimulate the afferent nerves cause fatigue.
수소이온 역시 암모니아와 젖산과 같이 혈중 피로물질 중 하나이다. 근육 내 수소이온 농도(pH)는 대략 7.0 정도이고 최대 운동 후 피로 시에 6.3∼6.5 정도로 변하게 된다. 운동에 따른 수소이온 농도의 저하는 운동 중인 근육에 많은 양의 이산화탄소와 젖산을 생성하게 되고 이러한 젖산은 강산으로 이온화하여 수소 이온을 방출하게 되는데, 방출된 수소이온의 양이 증가함에 따라 혈중 수소이온 농도는 감소하게 된다.Hydrogen ions are also one of the blood fatigue substances such as ammonia and lactic acid. The pH in the muscle is about 7.0 and changes from 6.3 to 6.5 at maximum fatigue after maximal exercise. The decrease in hydrogen ion concentration due to exercise produces a large amount of carbon dioxide and lactic acid in the muscles in motion. This lactic acid ionizes into strong acid and releases hydrogen ions. As the amount of released hydrogen ions increases, The concentration decreases.
본 발명자들은 혈중 피로 물질의 농도를 감소시켜 빠른 피로 개선에 효과를 나타내는 식품 조성물을 발견함으로써 본 발명을 완성하였다.
The present inventors have completed the present invention by discovering a food composition which is effective in reducing fatigue substance concentration in the blood and thereby improving fatigue quickly.
[비특허문헌 1] 윤성진 등, 한국사회체육학회지, 47, pp855-866, 2012[Non-Patent Document 1] Yoon SJ, et al., Journal of Korean Society of Physical Education, 47, pp855-866, 2012
[비특허문헌 2] 이명천 등, 라이프사이언스, pp17-19, 2012[Non-Patent Document 2] Lee, Myeongcheon et al., Life Science, pp17-19, 2012
[비특허문헌 3] Sherman, W. M., Medicine and Science in Sports and Exercise, 21:598-604, 1989[Non-Patent Document 3] Sherman, WM, Medicine and Science in Sports and Exercise, 21: 598-604, 1989
[비특허문헌 4] Jeukendrup, A. E., Carbohydrate feeding during exercise, 8(2):77-86, 2008[Non-patent Document 4] Jeukendrup, AE, Carbohydrate feeding during exercise , 8 (2): 77-86, 2008
[비특허문헌 5] 김재호 등, 한국체육교육학회지, 8(1), pp224-232, 2003[Non-Patent Document 5] Kim Jae-ho et al., Korean Physical Education Journal, 8 (1), pp224-232, 2003
[비특허문헌 6] 임기원 등, 운동영양학회지, 5(2), pp1-12, 2001
[Non-Patent Document 6] KIM Ki-won et al., Journal of Exercise Nutrition, 5 (2), pp1-12, 2001
따라서, 본 발명의 목적은 운동 후 빠른 근육 피로 개선에 효과적인 식품 조성물을 제공하는 것이다.
It is therefore an object of the present invention to provide a food composition effective for rapid muscle fatigue improvement after exercise.
상기 목적을 달성하기 위해 본 발명은, 가수분해 유청 단백(Whey protein hydrolysates, WPH) 분말 100 중량부를 기준으로, 대두 펩타이드 30 내지 35중량부; 난백 분말 8 내지 12중량부; 아미노산 25 내지 30중량부; 미네랄(무기영양소) 10 내지 15중량부; 비타민 1 내지 5중량부; 팔라티노스 10 내지 15중량부; 무수구연산 25 내지 30중량부; 결정 과당 19 내지 25중량부; 및 함수 결정 포도당 10 내지 15중량부를 포함하는, 운동 후 근육 피로 개선용 식품 조성물을 제공한다.
In order to accomplish the above object, the present invention provides a method for producing a whey protein hydrolyzate (WPH) comprising 30 to 35 parts by weight of a soybean peptide, 8 to 12 parts by weight of egg white powder; 25 to 30 parts by weight of amino acids; 10 to 15 parts by weight of minerals (inorganic nutrients); 1 to 5 parts by weight of vitamins; 10 to 15 parts by weight of palatinose; 25 to 30 parts by weight of anhydrous citric acid; 19 to 25 parts by weight of fructose crystals; And 10 to 15 parts by weight of hydrous crystalline glucose.
본 발명에 따른 근육 피로 개선용 식품 조성물은 혈중 피로물질인 암모니아 및 스트레스 호르몬인 코티졸의 농도를 감소시키고, 수소이온의 농도를 증가시킬 수 있으므로 운동 후 근육 피로 개선을 위한 운동보조제로서 유용하게 사용될 수 있다.
The food composition for improving muscle fatigue according to the present invention can reduce the concentration of ammonia which is a blood fatigue substance and cortisol which is a stress hormone and increase the concentration of hydrogen ions and thus can be usefully used as an exercise supplement for improving muscle fatigue after exercise have.
도 1은 테스트 전 및 후에 측정한 본 발명의 조성물의 단기 섭취에 따른 최대파워, 평균파워 및 피로지수 수치를 그래프로 나타낸 것이다.
도 2 내지 5는 각각 테스트 전 및 후에 측정한 본 발명의 조성물의 단기 섭취에 따른 코티졸, 암모니아, 젖산 및 수소 이온 농도의 수치를 그래프로 나타낸 것이다.FIG. 1 is a graph showing maximum power, average power and fatigue index values according to the short-term intake of the composition of the present invention measured before and after the test.
Figs. 2 to 5 are graphs showing the values of cortisol, ammonia, lactic acid and hydrogen ion concentration according to the short-term intake of the composition of the present invention measured before and after the test, respectively.
본 발명은 가수분해 유청 단백(Whey protein hydrolysates, WPH) 분말 100 중량부를 기준으로, 대두 펩타이드 30 내지 35중량부; 난백 분말 8 내지 12중량부; 아미노산 25 내지 30중량부; 미네랄(무기영양소) 10 내지 15중량부; 비타민 1 내지 5중량부; 팔라티노스 10 내지 15중량부; 무수구연산 25 내지 30중량부; 결정 과당 19 내지 25중량부; 및 함수 결정 포도당 10 내지 15중량부를 포함하는, 운동 후 근육 피로 개선용 식품 조성물을 제공한다. The present invention relates to a process for preparing whey protein hydrolyzates (WPH), which comprises 30 to 35 parts by weight of a soybean peptide based on 100 parts by weight of whey protein hydrolyzates (WPH) powder; 8 to 12 parts by weight of egg white powder; 25 to 30 parts by weight of amino acids; 10 to 15 parts by weight of minerals (inorganic nutrients); 1 to 5 parts by weight of vitamins; 10 to 15 parts by weight of palatinose; 25 to 30 parts by weight of anhydrous citric acid; 19 to 25 parts by weight of fructose crystals; And 10 to 15 parts by weight of hydrous crystalline glucose.
바람직하게는, 상기 조성물은 WPH 분말 100 중량부를 기준으로, 대두 펩타이드 32 내지 34중량부; 난백 분말 9 내지 11중량부; 아미노산 26 내지 28중량부; 미네랄(무기영양소) 11 내지 13중량부; 비타민 2 내지 4중량부; 팔라티노스 12 내지 14중량부; 무수구연산 27 내지 29중량부; 결정 과당 21 내지 23중량부; 및 함수 결정 포도당 12 내지 14중량부를 포함할 수 있다.Preferably, the composition comprises, based on 100 parts by weight of WPH powder, 32 to 34 parts by weight of a soybean peptide; 9 to 11 parts by weight of egg white powder; 26 to 28 parts by weight of amino acids; 11 to 13 parts by weight of minerals (inorganic nutrients); 2 to 4 parts by weight of vitamins; 12 to 14 parts by weight of palatinose; 27 to 29 parts by weight of anhydrous citric acid; 21 to 23 parts by weight of crystalline fructose; And 12 to 14 parts by weight of hydrous crystalline glucose.
본 발명의 일 실시양태에 따르면 상기 조성물은 WPH 분말 100 중량부를 기준으로, 대두 펩타이드 약 33.33중량부; 난백 분말 약 10.00중량부; 아미노산 약 26.84중량부; 미네랄(무기영양소) 약 12.32중량부; 비타민 약 3.33중량부; 팔라티노스 약 13.33중량부; 무수구연산 약 28.50중량부; 결정 과당 약 21.67중량부; 및 함수 결정 포도당 약 13.33중량부를 포함한다.
According to one embodiment of the present invention, the composition comprises about 33.33 parts by weight of a soybean peptide, based on 100 parts by weight of WPH powder; About 10.00 parts by weight of egg white powder; About 26.84 parts by weight of amino acids; About 12.32 parts by weight of minerals (inorganic nutrients); About 3.33 parts by weight of vitamin; About 13.33 parts by weight palatinose; About 28.50 parts by weight of anhydrous citric acid; About 21.67 parts by weight of fructose crystals; And about 13.33 parts by weight of hydrous crystalline glucose.
본 발명에서 아미노산은 아르기닌, 이소로이신, 발린, 글루타민, 로이신, 알라닌, 아스파라긴, 아스파라긴산, 히스티딘, 트레오닌 및 이의 혼합물로 이루어진 군에서 선택될 수 있으나, 이에 한정되는 것은 아니다. 바람직하게는 아르기닌, 이소로이신, 발린, 글루타민, 로이신, 알라닌, 아스파라긴 및 아스파라긴산을 혼합하여 사용할 수 있다. 이들의 함량은, 예를 들어 WPH 분말 100 중량부를 기준으로, 아르기닌 0.2 내지 3중량부, 이소로이신 0.3 내지 4중량부, 발린 0.3 내지 4중량부, 글루타민 0.6 내지 7중량부, 로이신 0.6 내지 7중량부, 알라닌 0.28 내지 3중량부, 아스파라긴 0.52 내지 5중량부 및 아스파라긴산 0.52 내지 5중량부일 수 있다.
In the present invention, the amino acid may be selected from the group consisting of arginine, isoleucine, valine, glutamine, leucine, alanine, asparagine, aspartic acid, histidine, threonine and mixtures thereof. Preferably, arginine, isoleucine, valine, glutamine, leucine, alanine, asparagine and aspartic acid may be mixed and used. The content thereof is, for example, 0.2 to 3 parts by weight of arginine, 0.3 to 4 parts by weight of isoleucine, 0.3 to 4 parts by weight of valine, 0.6 to 7 parts by weight of glutamine, 0.6 to 7 parts by weight of rosin, 0.28 to 3 parts by weight of alanine, 0.52 to 5 parts by weight of asparagine and 0.52 to 5 parts by weight of aspartic acid.
본 발명에서 미네랄(무기영양소)는 황산 마그네슘, 글루콘산 칼슘, 젖산 칼슘, 구연산 칼륨, 산화아연, 판토텐산 칼슘, 니코틴산아미드, 엽산, 구리, 철, 망간, 몰리브덴 및 이의 혼합물로 이루어진 군에서 선택될 수 있으나, 이에 한정되는 것은 아니다. 바람직하게는, 황산 마그네슘, 글루콘산 칼슘, 젖산 칼슘, 구연산 칼륨, 산화아연, 니코틴산 아미드, 판토텐산 칼슘 및 엽산을 혼합하여 사용할 수 있다. 이들의 함량은, 예를 들어 WPH 분말 100 중량부를 기준으로, 황산 마그네슘 1 내지 5중량부, 글루콘산 칼슘 1 내지 3중량부, 젖산 칼슘 1 내지 3중량부, 구연산 칼륨 1 내지 5중량부, 산화아연 2 내지 4중량부, 니코틴산 아미드 1 내지 2중량부, 판토텐산 칼슘 0.5 내지 1중량부 및 엽산 0.01 내지 0.05중량부일 수 있다.
Minerals (inorganic nutrients) in the present invention may be selected from the group consisting of magnesium sulfate, calcium gluconate, calcium lactate, potassium citrate, zinc oxide, calcium pantothenate, nicotinamide, folic acid, copper, iron, manganese, molybdenum, However, the present invention is not limited thereto. Preferably, magnesium sulfate, calcium gluconate, calcium lactate, potassium citrate, zinc oxide, nicotinamide, calcium pantothenate and folic acid can be used in combination. The content thereof is, for example, 1 to 5 parts by weight of magnesium sulfate, 1 to 3 parts by weight of calcium gluconate, 1 to 3 parts by weight of calcium lactate, 1 to 5 parts by weight of potassium citrate, 2 to 4 parts by weight of zinc, 1 to 2 parts by weight of nicotinic acid amide, 0.5 to 1 part by weight of calcium pantothenate and 0.01 to 0.05 part by weight of folic acid.
본 발명에서 비타민은 비타민 B1, 비타민 B2, 비타민 B6, 비타민 B12, 이의 염 및 이의 혼합물로 이루어진 군에서 선택될 수 있으나, 이에 한정되는 것은 아니다. 바람직하게는, 비타민 B2, 비타민 B6 염산염, 비타민 B1 염산염 및 비타민 B12를 혼합하여 사용할 수 있다. 이들의 함량은, 예를 들어 WPH 분말 100 중량부를 기준으로, 비타민 B2 0.02 내지 0.3중량부, 비타민 B6 염산염 0.03 내지 0.3중량부, 비타민 B1 염산염 0.023 내지 0.3중량부 및 비타민 B12 0.015 내지 0.2중량부일 수 있다.
In the present invention, the vitamin may be selected from the group consisting of vitamin B1, vitamin B2, vitamin B6, vitamin B12, a salt thereof, and a mixture thereof, but is not limited thereto. Preferably, vitamin B2, vitamin B6 hydrochloride, vitamin B1 hydrochloride and vitamin B12 can be mixed and used. These ingredients may be, for example, 0.02 to 0.3 parts by weight of vitamin B2, 0.03 to 0.3 part by weight of vitamin B6 hydrochloride, 0.023 to 0.3 part by weight of vitamin B1 hydrochloride, and 0.015 to 0.2 part by weight of vitamin B12 based on 100 parts by weight of WPH powder have.
본 발명의 조성물은 식물 추출물, 감미제, 향미제, 안정제, 과즙, 식이섬유, 고결 방지제 및 이의 조합으로 이루어진 군에서 선택되는 식품학적으로 허용 가능한 첨가제를 더 포함할 수 있다.
The composition of the present invention may be applied to plant extracts, sweeteners, flavors, stabilizers, fruit juices, dietary fibers, anticaking agents ≪ / RTI > and combinations thereof.
본 발명에서 사용가능한 식물 추출물은 과라나 추출물, 치커리뿌리 추출물, 열대 과일 추출물, 허브 추출물 및 이의 조합으로 이루어진 군에서 선택될 수 있으며, 바람직하게는 10% 과라나 추출물을 사용할 수 있다. The plant extracts usable in the present invention may be selected from the group consisting of guarana extract, chicory root extract, tropical fruit extract, herbal extract and combinations thereof, preferably 10% guarana extract.
상기 식물 추출물은 WPH 분말 100 중량부를 기준으로 3 내지 6중량부, 바람직하게는 4 내지 5중량부의 양으로 포함될 수 있다.
The plant extract may be contained in an amount of 3 to 6 parts by weight, preferably 4 to 5 parts by weight, based on 100 parts by weight of the WPH powder.
본 발명에서 사용가능한 감미제는 아스파탐, 에리스리톨, 결정 과당 및 이의 혼합물로 이루어진 군에서 선택될 수 있으며, 바람직하게는 아스파탐 및 에리스리톨을 혼합하여 사용할 수 있다. The sweetening agent which can be used in the present invention may be selected from the group consisting of aspartame, erythritol, crystalline fructose and a mixture thereof, preferably aspartame and erythritol.
상기 감미제는 WPH 분말 100 중량부를 기준으로 8 내지 10중량부, 바람직하게는 9 내지 10중량부의 양으로 포함될 수 있다. 아스파탐 및 에리스리톨을 혼합 사용하는 경우, 이들은 WPH 분말 100 중량부를 기준으로 아스파탐 1 내지 5중량부, 바람직하게는 3 내지 4중량부; 및 에리스리톨 3 내지 8중량부, 바람직하게는 5 내지 7중량부의 양으로 포함될 수 있다.
The sweetener may be contained in an amount of 8 to 10 parts by weight, preferably 9 to 10 parts by weight, based on 100 parts by weight of the WPH powder. When aspartame and erythritol are mixed, they are used in an amount of 1 to 5 parts by weight, preferably 3 to 4 parts by weight, based on 100 parts by weight of WPH powder; And erythritol in an amount of 3 to 8 parts by weight, preferably 5 to 7 parts by weight.
본 발명에서 사용가능한 향미제는 레몬향 분말, 사과향 분말, 포도향 분말, 라임향 분말, 석류향 분말, 오렌지향 분말, 체리향 분말 및 이의 혼합물로 이루어진 군에서 선택될 수 있으며, 바람직하게는 레몬향 분말 및 사과향 분말을 혼합하여 사용할 수 있다. The flavoring agents usable in the present invention may be selected from the group consisting of lemon flavor powder, apple flavor powder, grape flavor powder, lime flavor powder, gruel powder, orange flavor powder, cherry flavor powder and mixtures thereof, Powder and an apple-like powder may be mixed and used.
상기 향미제는 WPH 100 중량부를 기준으로 10 내지 15중량부, 바람직하게는 12 내지 14중량부의 양으로 포함될 수 있다. 레몬향 분말 및 사과향 분말을 혼합 사용하는 경우, 이들은 WPH 분말 100 중량부를 기준으로 레몬향 분말 5 내지 8중량부, 바람직하게는 6 내지 7중량부; 및 사과향 분말 5 내지 8중량부, 바람직하게는 6 내지 7중량부의 양으로 포함될 수 있다.
The flavoring agent may be contained in an amount of 10 to 15 parts by weight, preferably 12 to 14 parts by weight based on 100 parts by weight of WPH. When mixed with lemon fragrance powder and apple fruit powder, they are used in an amount of 5 to 8 parts by weight, preferably 6 to 7 parts by weight, based on 100 parts by weight of WPH powder, of lemon fragrant powder; And 5 to 8 parts by weight, preferably 6 to 7 parts by weight of an apple-like powder.
본 발명에서 사용가능한 안정제는 베타 싸이클로덱스트린, 구아검, 이산화규소, 하이드록시프로필메틸 셀룰로오스(HPMC), 옥수수 추출물 및 이의 조합으로 이루어진 군에서 선택될 수 있으며, 바람직하게는 베타 싸이클로덱스트린과 구아검을 혼합하여 사용할 수 있다. The stabilizers usable in the present invention may be selected from the group consisting of betacyclodextrin, guar gum, silicon dioxide, hydroxypropyl methylcellulose (HPMC), corn extract and combinations thereof, preferably beta-cyclodextrin and guar gum Can be used.
상기 안정제는 WPH 분말 100 중량부를 기준으로 5 내지 10중량부, 바람직하게는 7 내지 9중량부의 양으로 포함될 수 있다. 베타 싸이클로덱스트린과 구아검을 혼합하여 사용하는 경우, 이들은 WPH 분말 100 중량부를 기준으로 베타 싸이클로덱스트린 3 내지 7중량부, 바람직하게는 4 내지 6중량부; 및 구아검 3 내지 7중량부, 바람직하게는 4 내지 5중량부의 양으로 포함될 수 있다.
The stabilizer may be included in an amount of 5 to 10 parts by weight, preferably 7 to 9 parts by weight, based on 100 parts by weight of the WPH powder. When a mixture of beta cyclodextrin and guar gum is used, they are used in an amount of 3 to 7 parts by weight, preferably 4 to 6 parts by weight, based on 100 parts by weight of WPH powder, of a betacyclodextrin; And guar gum in an amount of 3 to 7 parts by weight, preferably 4 to 5 parts by weight.
본 발명에서 사용가능한 과즙은 레몬 과즙 분말 및 이의 혼합물로 이루어진 군에서 선택될 수 있으며, 바람직하게는 레몬 과즙 분말을 사용할 수 있다. The juice usable in the present invention may be selected from the group consisting of lemon juice powder and mixtures thereof, preferably lemon juice powder.
상기 과즙은 WPH 분말 100 중량부를 기준으로 14 내지 19중량부, 바람직하게는 15 내지 17중량부의 양으로 포함될 수 있다.
The juice may be contained in an amount of 14 to 19 parts by weight, preferably 15 to 17 parts by weight, based on 100 parts by weight of the WPH powder.
본 발명에서 사용가능한 식이섬유는 치커리 식이섬유(치커리 뿌리 추출물 분말), 프락토올리고당, 난소화성말토덱스트린 및 이의 혼합물로 이루어진 군에서 선택될 수 있으며, 바람직하게는 치커리 식이섬유를 사용할 수 있다. The dietary fibers usable in the present invention include chicory dietary fiber (chicory root extract powder), fructooligosaccharide, indigestible maltodextrin And a mixture thereof, and chicory dietary fiber can be preferably used.
상기 식이섬유는 WPH 분말 100 중량부를 기준으로 14 내지 19중량부, 바람직하게는 15 내지 17중량부의 양으로 포함될 수 있다.
The dietary fiber may be contained in an amount of 14 to 19 parts by weight, preferably 15 to 17 parts by weight, based on 100 parts by weight of the WPH powder.
본 발명에서 사용가능한 고결 방지제는 이산화규소, 히드록시프로필메틸셀룰로오스(HPMC) 및 이의 혼합물로 이루어진 군에서 선택될 수 있으며, 바람직하게는 이산화규소를 사용할 수 있다. The anticaking agent usable in the present invention may be selected from the group consisting of silicon dioxide, hydroxypropyl methylcellulose (HPMC), and mixtures thereof, preferably silicon dioxide.
상기 고결방지제는 WPH 분말 100 중량부를 기준으로 0.5 내지 1.5중량부, 바람직하게는 0.8 내지 1.1중량부의 양으로 포함될 수 있다.
The anticaking agent may be contained in an amount of 0.5 to 1.5 parts by weight, preferably 0.8 to 1.1 parts by weight based on 100 parts by weight of the WPH powder.
본 발명의 바람직한 실시양태에 따르면, 본 발명의 식품 조성물은 WPH 분말 100 중량부를 기준으로, 대두 펩타이드 32 내지 34중량부; 난백 분말 9 내지 11중량부; 아미노산 26 내지 28중량부; 미네랄(무기영양소) 11 내지 13중량부; 비타민 2 내지 4중량부; 팔라티노스 12 내지 14중량부; 무수구연산 27 내지 29중량부; 결정 과당 21 내지 23중량부; 함수 결정 포도당 12 내지 14중량부; 10% 과라나 추출물 4 내지 5중량부; 아스파탐 3 내지 4중량부; 에리스리톨 5 내지 7중량부; 구아검 4 내지 5중량부; 레몬향 분말 6 내지 7중량부; 사과향 분말 6 내지 7중량부; 베타 싸이클로덱스트린 4 내지 6중량부; 레몬 과즙 분말 15 내지 17중량부; 치커리 식이섬유 15 내지 17중량부; 및 이산화규소 0.8 내지 1.1중량부를 포함할 수 있다.
According to a preferred embodiment of the present invention, the food composition of the present invention comprises 32 to 34 parts by weight of a soybean peptide, based on 100 parts by weight of WPH powder; 9 to 11 parts by weight of egg white powder; 26 to 28 parts by weight of amino acids; 11 to 13 parts by weight of minerals (inorganic nutrients); 2 to 4 parts by weight of vitamins; 12 to 14 parts by weight of palatinose; 27 to 29 parts by weight of anhydrous citric acid; 21 to 23 parts by weight of crystalline fructose; 12 to 14 parts by weight of hydrous crystalline glucose; 4 to 5 parts by weight of 10% guarana extract; 3 to 4 parts by weight of aspartame; 5 to 7 parts by weight of erythritol; 4 to 5 parts by weight of guar gum; 6 to 7 parts by weight of lemon fragrant powder; 6 to 7 parts by weight of an apple fruit powder; 4 to 6 parts by weight of betacyclodextrin; 15 to 17 parts by weight of lemon juice powder; 15 to 17 parts by weight of Chicory dietary fiber; And 0.8 to 1.1 parts by weight of silicon dioxide.
상기 성분 이외에도, 본 발명의 조성물은 식품학적으로 허용되는, 운동 보조를 위한 기타의 천연 또는 합성 물질 및 제품화를 위한 첨가물, 여러가지 영양제, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 안정화제 등을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다.
In addition to the above components, the composition of the present invention can be used as a foodstuff, other natural or synthetic substances for exercise aids, additives for commercialization, various nutrients, minerals (electrolytes), synthetic flavors and flavors such as natural flavors , Stabilizers, and the like. These components may be used independently or in combination.
본 발명에 따른 운동 후 근육 피로 개선용 식품 조성물을 이용하여 통상의 식품학적 가공 방법에 따라 다양한 형태의 기능성 식품을 제조할 수 있다. 따라서, 본 발명은 상기 식품 조성물로부터 제조된 운동 후 근육 피로 개선용 식품을 제공한다.Various forms of functional foods can be prepared according to conventional food processing methods using the food composition for improving muscle fatigue after exercise according to the present invention. Accordingly, the present invention provides a post-exercise muscle fatigue improving food prepared from the food composition.
본 발명의 운동 후 근육 피로 개선용 식품은 바람직하게는 분말의 형태이며, 이로부터 식품학적 가공 방법에 따라 가공된 과립, 정제, 캡슐, 액상(음료), 파우더 또는 겔(젤) 형태일 수도 있다. 분말 형태인 본 발명의 식품은 예를 들어 물과 같은 매질에 현탁시켜 음용할 수 있다.
The post-exercise muscle fatigue improving food of the present invention is preferably in the form of a powder and may be in the form of a granule, a tablet, a capsule, a liquid (beverage), a powder or a gel (gel) . The food of the present invention in powder form may be suspended in a medium such as water for example.
본 발명에 따른 조성물은 혈중 피로물질인 암모니아, 코티졸 및 젖산의 농도를 감소시키고 수소이온의 농도(pH)를 빠르게 증가시킬 수 있으므로 운동 후 빠른 피로 개선에 효과를 나타낼 수 있다.
The composition according to the present invention can reduce the concentration of ammonia, cortisol and lactic acid, which are fatigue substances in blood, and can rapidly increase the concentration of hydrogen ions (pH), so that the composition can exhibit rapid fatigue improvement after exercise.
[실시예][Example]
이하, 본 발명을 하기 실시예에 의하여 더욱 상세하게 설명한다. 단, 하기 실시예는 본 발명을 예시하기 위한 것일 뿐, 본 발명의 범위가 이들만으로 한정되는 것은 아니다.
Hereinafter, the present invention will be described in more detail with reference to the following examples. However, the following examples are for illustrative purposes only and are not intended to limit the scope of the present invention.
실시예 1: 운동 후 근육 피로 개선용 식품 조성물의 제조Example 1: Preparation of a food composition for improving muscle fatigue after exercise
하기 표 1에 기재된 성분 및 함량비를 이용하여 본 발명의 운동 후 근육 피로 개선용 식품 조성물(이하, "패스트 리커버"로 지칭함)을 제조하였다. (Hereinafter referred to as "fast recovery") of the present invention was prepared using the components and the content ratios shown in Table 1 below.
구체적으로, 기준 및 규격에 적합하고 이물이 없는 성분들을 원료로 하고, 제조에 사용되는 기구는 이물질 혼입이나 미생물 오염을 방지할 수 있도록 세척 및 살균 소독하여 사용하였다. 하기 표 1에 기재된 성분 및 배합 비율에 따라 정확히 칭량한 후 혼합기(입수처: 일성기공)에 원료를 투입한 후 10 내지 14 rpm으로 30분간 균질화하여 혼합 파우더 형태의 식품 조성물을 제조하였다. 균질화된 내용물을 적량 충진기(입수처: 서울엔지니어링)에 충진하고, 통상적인 포장방법에 따라 포장한 후, 품질 관리 시험을 합격한 제품들만 출하하였다. Specifically, the components used in the manufacturing process were cleaned and disinfected so as to prevent foreign matter contamination or microbial contamination. The ingredients were precisely weighed according to the ingredients and blending ratios shown in Table 1, and then the raw materials were added to a mixer (raw material pore) and homogenized at 10 to 14 rpm for 30 minutes to prepare a mixed powder type food composition. The homogenized contents were packed in an appropriate filling machine (available from Seoul Engineering), packed according to the usual packaging method, and only the products passed the quality control test were shipped.
이때, MegaAmino 믹스(분말)는 믹스 총 중량을 기준으로 아르기닌 10중량%, 이소로이신 15중량%, 발린 15중량%, 글루타민 30중량% 및 로이신 30중량%을 드럼 믹서에 투입한 후 혼합함으로써 제조하였다. At this time, the MegaAmino mix (powder) was prepared by adding 10 weight% of arginine, 15 weight% of isoleucine, 15 weight% of valine, 30 weight% of glutamine and 30 weight% of leucine to the drum mixer based on the total weight of the mix .
A3C 믹스는 믹스 총 중량을 기준으로 알라닌 13중량%, 아스파라긴 24중량%, 아스파르트산 24중량% 및 구연산 39중량%을 드럼 믹서에 투입한 후 혼합함으로써 제조하였다. The A3C mix was prepared by charging
또한, 비타민B군 믹스DS는 믹스 총 중량을 기준으로 니코틴산 아미드 54.1140중량%, 판토텐산 칼슘 22.9374중량%, 비타민 B6 염산염 7.6098중량%, 비타민 B1 염산염 5.5168중량%, 비타민 B2 5.0784중량%, 엽산 1.0667중량% 및 비타민 B12 3.6770중량%(비타민 B12 0.1%, 구연산나트륨 3%, 구연산 1% 및 덱스트린 95.9% 함유)를 드럼 믹서에 투입한 후 혼합함으로써 제조하였다.
The vitamin B group mix DS contained 54.1140 wt% of niacinamide, 22.9374 wt% of calcium pantothenate, 7.6098 wt% of vitamin B6 hydrochloride, 5.5168 wt% of vitamin B1 hydrochloride, 5.0784 wt% of vitamin B2, 1.0667 wt% of folic acid, And 3.6770% by weight of vitamin B12 (containing 0.1% of vitamin B12, 3% of sodium citrate, 1% of citric acid and 95.9% of dextrin) into a drum mixer and mixing.
실험예 1Experimental Example 1 : 패스트 리커버 단기 섭취에 따른 운동 에너지 보충 효과: Supplementation effect of kinetic energy according to fast recovery short term intake
상기 실시예 1에서 제조한 조성물의 단기 섭취에 따른 임상 효과를 알아보기 위해, 질환이 없는 건강한 20대 성인 남녀 20명에게 사전에 실험내용을 충분히 설명하고 문진과 기초설문지 및 동의서를 작성하게 하였다.
To examine the clinical effects of the composition prepared in Example 1 according to the short-term intake, 20 healthy male and female 20 healthy persons without disease were explained in detail beforehand, and the questionnaires, basic questionnaires and consent forms were prepared.
패스트 리커버 섭취 시기Fast recovery time
실험 일주일 전에 윈게이트 테스트를 수행하였고, 섭취 그룹은 패스트 리커버를 용량별(13g 및 26g)로 7일 간격으로 섭취하도록 하였으며, 이때 섭취 시기는 실험 전날 13시 및 18시, 및 실험 당일에 윈게이트 테스트를 수행한 직후에 섭취하도록 하였다. 보다 명백한 효과를 검토하기 위해서 비섭취군(대조그룹)에 대한 평가도 함께 실시하였다.
The winking test was performed one week before the experiment, and the fasting group was consumed at 7 days intervals (13 g and 26 g) by the dose group. At this time, the consumption time was 13 and 18 on the day before the experiment, It was taken immediately after the test. In order to examine the more obvious effects, non-intake group (control group) was also evaluated.
측정 방법How to measure
(1) 최대파워 및 평균파워(1) maximum power and average power
30초 동안 자전거 에르고미터를 실시하여 윈게이트 테스트를 하였으며, 최대파워, 평균파워 및 피로지수를 측정하였다.
The bicycle ergometer was run for 30 seconds, and the maximum power, average power and fatigue index were measured.
(2) 젖산, 코티졸, 암모니아 및 수소이온 농도(2) Lactic acid, cortisol, ammonia and hydrogen ion concentration
윈게이트 테스트 동안 테스트 전(rest)과 직후(all out), 그리고 테스트 종료 15분, 30분 및 60분 후에 각각 채혈을 실시하였고, 혈액분석을 통해 젖산, 코티졸, 암모니아 및 수소이온 농도를 검사하였다.Blood samples were collected at rest and all out during the Wingate test and at 15, 30, and 60 minutes after the end of the test. Lactic acid, cortisol, ammonia, and hydrogen ion concentrations were tested by blood analysis .
실험 대상자들은 최소 9시간 이상 공복상태를 유지한 상태에서 실험실을 방문하였으며, 채혈 전 30분 이상 의자에 앉아 안정을 취하게 한 후 상완정맥에서 10ml의 혈액을 채혈하였다. 그룹 간 동일한 시간대와 방법으로 채혈을 실시하였다. 채혈된 혈액은 혈장과 혈청으로 분리한 후 젖산, 코티졸, 암모니아 및 수소이온 농도를 측정하는데 사용하였다.The subjects visited the laboratory with at least 9 hours of fasting state. After sitting for 30 minutes or more in the chair, blood was taken from the upper arm vein. Blood samples were collected at the same time intervals between groups. The collected blood was separated into plasma and serum and used to measure lactate, cortisol, ammonia, and hydrogen ion concentration.
코티졸, 젖산 및 수소이온의 활성도를 분석하기 위해, 채혈된 혈액을 SST 튜브에 약 5ml을 넣은 후 30분 동안 상온에서 방치시켰고, 그 후 3000rpm으로 15분 동안 원심분리하여 혈청을 분리하였다.In order to analyze the activity of cortisol, lactic acid and hydrogen ions, about 5 ml of the collected blood was put in the SST tube and left at room temperature for 30 minutes. Then, the serum was separated by centrifugation at 3000 rpm for 15 minutes.
또한 암모니아를 분석하기 위해 EDTA 튜브에 채혈된 혈액 4ml을 넣고 3000rpm에서 15분 동안 원심분리 하여 혈장을 분리하였다. To analyze ammonia, 4 ml of blood collected in an EDTA tube was added and the plasma was separated by centrifugation at 3000 rpm for 15 minutes.
혈중 젖산 농도는 젖산 분석기(BIOSEN_Cline, Germany)를 사용하였으며, 코티졸, 암모니아 및 수소이온 농도는 SQ Lab(Sure Quest Lab)에 의뢰하여 각각의 혈중 농도를 분석하였다.
The concentration of lactate in the blood was determined using a lactic acid analyzer (BIOSEN_Cline, Germany), and cortisol, ammonia and hydrogen ion concentrations were determined by SQ Lab (Sure Quest Lab).
통계처리 방법Statistical processing method
자료처리는 SPSS 18.0을 이용하여 각 항목별 평균 및 표준편차를 산출하였다. 윈게이트 검사에 따른 측정변인에 대한 차이 검증은 One-way ANOVA로 실시하였고, 혈중 피로물질 측정변인에 대한 차이검증은 Two-way mixed ANOVA(시점×집단)로 실시하였다. 통계학적 유의수준(α)은 .05로 설정하였다.
Data were processed by using SPSS 18.0 to calculate mean and standard deviation for each item. One-way ANOVA was used to verify the difference of the measurement variables according to the Wingate test, and two-way mixed ANOVA (viewpoint × group) was used to verify the difference in blood fatigue substance measurement variables. Statistical significance level (α) was set at .05.
결과result
최대파워, 평균파워 및 피로지수의 변화Changes in peak power, average power and fatigue index
단기간 패스트 리커버 섭취에 따른 그룹별 최대파워, 평균파워 및 피로지수의 변화를 하기 표 2 및 도 1에 나타내고, 이의 일원 변량 분석결과를 표 3에 나타내었다. Table 2 and FIG. 1 show the changes of the maximum power, average power and fatigue index according to short-term fast recovery ingestion, and the results of the one-way ANOVA analysis are shown in Table 3.
표 3에서 보는 바와 같이, 최대파워와 평균파워 변화를 살펴보면 대조그룹에 비해 13g 섭취그룹과 26g 섭취그룹 모두에서 증가된 것으로 나타났다. 또한 피로지수 변화에서는 대조그룹에 비해 26g 섭취그룹이 감소경향을 보이는 것으로 나타났다.
As shown in Table 3, the maximum power and average power changes were increased in both the 13 g intake group and the 26 g intake group compared to the control group. In the fatigue index change, 26g intake group showed a tendency to decrease compared to the control group.
코티졸, 암모니아, 젖산 및 수소이온 농도의 변화Changes in cortisol, ammonia, lactic acid and hydrogen ion concentrations
단기간 패스트 리커버 섭취에 따른 그룹별 코티졸, 암모니아, 젖산 및 수소이온 농도의 변화를 하기 표 4에 나타내었다. Changes in cortisol, ammonia, lactate, and hydrogen ion concentrations by group of short-term fast recovery ingestion are shown in Table 4 below.
(1) 코티졸 농도(1) cortisol concentration
정상적인 농도의 코티졸은 스트레스에 대항하여 신체를 돕는 역할을 한다. 그러나 매우 높은 농도의 코티졸은 발열을 억제하고 면역기능을 상실하게 한다(정희정 등, 한국사회체육학회지, 35, pp973-980 (2009)). The normal concentration of cortisol acts to help the body against stress. However, very high concentrations of cortisol inhibit fever and lead to loss of immune function (Jeong, Hee-jung et al., Journal of Korean Society for Physical Education, 35, pp973-980 (2009)).
단기간 패스트 리커버 섭취에 따른 그룹내, 그룹간 코티졸 농도 (㎍/㎗) 변화의 이원 변량 분석 결과를 하기 표 5 및 도 2에 나타내었다. The results of the double-variable analysis of changes in cortisol concentration (㎍ / ㎗) between groups and between groups according to short-term fast recovery ingestion are shown in Table 5 and FIG.
표 5에서 보는 바와 같이, 코티졸 농도는 그룹 내에서는 통계적으로 유의한 차이가 나타난 반면(p<.001), 섭취그룹 간에는 유의한 차이가 없는 것으로 나타났다. 그러나 그룹과 시점간의 상호작용 효과가 있는 것으로 나타났다. As shown in Table 5, cortisol levels were statistically significant (p <.001) within the group, but there was no significant difference between the groups. However, it was found that there is an interaction effect between the group and the viewpoint.
도 2에서 보는 바와 같이, 대조그룹은 안정 시에 비해 회복 60분 시점에서 높은 수치를 나타내고 있으나, 패스트 리커버 13g 섭취그룹과 26g 섭취그룹에서는 안정 시와 회복 60분 시점의 코티졸 수준이 거의 비슷하게 나타났다. 이와 같은 결과는 단기간 동안 패스트 리커버를 섭취한 두 그룹 모두에서 코티졸 농도의 감소 효과가 있음을 확인할 수 있다.
As shown in FIG. 2, the control group showed a high value at 60 minutes of recovery compared with the resting group, but the cortisol levels at the time of resting and
(2) 암모니아 농도(2) Ammonia concentration
단기간 패스트 리커버 섭취에 따른 그룹내, 그룹간 암모니아 농도 (㎍/㎗) 변화의 이원 변량 분석 결과를 하기 표 6 및 도 3에 나타내었다. The results of the double-variable analysis of changes in intra-group and intra-group ammonia concentrations (/ / ㎗) due to short-term fast recovery ingestion are shown in Table 6 and FIG.
그 결과, 그룹내, 그룹간에 유의한 차이가 있고(p<.001), 그룹과 시점간에 상호작용 효과가 있는 것으로 나타났다. 그룹간의 사후검증(Duncan) 결과, 13g 섭취 그룹에서는 통계적으로 유의하게 효과가 있는 것으로 나타났다(p<.001). 상기 결과로부터 단기간 패스트 리커버를 섭취한 그룹 중 13g 섭취 그룹이 가장 효과가 있음을 확인할 수 있다(도 3).
As a result, there was a significant difference between group and group (p <.001), and there was an interaction effect between group and viewpoint. Duncan showed statistically significant effect in the 13g intake group (p <.001). From the above results, it can be confirmed that the 13 g intake group is the most effective among the groups consuming the short-term fast recovery (FIG. 3).
(3) 젖산 농도(3) Lactic acid concentration
단기간 패스트 리커버 섭취에 따른 그룹내, 그룹간 젖산 농도 (㎍/㎗) 변화의 이원 변량 분석 결과를 하기 표 7 및 도 4에 나타내었다. The results of the analysis of the two-way analysis of the changes in lactate concentration (㎍ / ㎗) between groups and between groups according to the short-term fast recovery ingestion are shown in Table 7 and FIG.
수치상으로는 대조그룹에 비해 패스트 리커버 13g 섭취그룹과 26g 섭취그룹에서의 시점별 증가폭이 작았다는 것을 확인할 수 있었다(도 4).
In comparison with the control group, it was confirmed that the increase in the time of the Fast Recover 13g intake group and the 26g intake group was smaller than that of the control group (FIG. 4).
(4) 수소이온 농도(4) Hydrogen ion concentration
단기간 패스트 리커버 섭취에 따른 그룹내, 그룹간 수소 이온농도 변화의 이원 변량 분석 결과를 하기 표 8 및 도 5에 나타내었다. The results of the analysis of the two-way variance of intra- and intergroup hydrogen ion concentration changes with short-term fast recovery ingestion are shown in Table 8 and FIG.
도 5에서 보는 바와 같이, 각 그룹내, 그룹간에서 통계적으로 유의한 차이가 있고, 그룹과 시점간에 상호작용 효과가 있는 것으로 나타났다(도 5). 대조그룹에 비해 패스트 리커버를 섭취한 두 그룹 모두에서 긍정적인 효과가 있는 것으로 나타났으며, 사후분석(Duncan) 결과에서는 대조그룹과 26g 섭취그룹에 비해 13g 섭취그룹이 .05수준에서 유의하게 증가한 것으로 나타났다.As shown in FIG. 5, there was a statistically significant difference between the groups and the groups, and there was an interaction effect between the groups and the viewpoint (FIG. 5). The Duncan results showed a significant increase in the 13 g intake group at the .05 level compared with the control group and the 26 g intake group in both groups receiving fast recovery compared to the control group appear.
Claims (14)
상기 조성물이 WPH 분말 100 중량부를 기준으로, 대두 펩타이드 32 내지 34중량부; 난백 분말 9 내지 11중량부; 아미노산 26 내지 28중량부; 미네랄(무기영양소) 11 내지 13중량부; 비타민 2 내지 4중량부; 팔라티노스 12 내지 14중량부; 무수구연산 27 내지 29중량부; 결정 과당 21 내지 23중량부; 및 함수 결정 포도당 12 내지 14중량부를 포함하는, 식품 조성물. The method according to claim 1,
Said composition comprising, based on 100 parts by weight of WPH powder, 32 to 34 parts by weight of a soybean peptide; 9 to 11 parts by weight of egg white powder; 26 to 28 parts by weight of amino acids; 11 to 13 parts by weight of minerals (inorganic nutrients); 2 to 4 parts by weight of vitamins; 12 to 14 parts by weight of palatinose; 27 to 29 parts by weight of anhydrous citric acid; 21 to 23 parts by weight of crystalline fructose; And from 12 to 14 parts by weight of hydrous crystalline glucose.
상기 아미노산이 아르기닌, 이소로이신, 발린, 글루타민, 로이신, 알라닌, 아스파라긴 및 아스파라긴산의 혼합물인 것을 특징으로 하는, 식품 조성물.The method according to claim 1,
Wherein the amino acid is a mixture of arginine, isoleucine, valine, glutamine, leucine, alanine, asparagine and aspartic acid.
상기 아미노산이 WPH 분말 100 중량부를 기준으로, 아르기닌 0.2 내지 3중량부, 이소로이신 0.3 내지 4중량부, 발린 0.3 내지 4중량부, 글루타민 0.6 내지 7중량부, 로이신 0.6 내지 7중량부, 알라닌 0.28 내지 3중량부, 아스파라긴 0.52 내지 5중량부 및 아스파라긴산 0.52 내지 5중량부를 포함하는 것을 특징으로 하는, 식품 조성물.The method of claim 3,
Wherein the amino acid is selected from the group consisting of 0.2 to 3 parts by weight of arginine, 0.3 to 4 parts by weight of isoleucine, 0.3 to 4 parts by weight of valine, 0.6 to 7 parts by weight of glutamine, 0.6 to 7 parts by weight of leucine, 3 to 5 parts by weight of asparagine, and 0.52 to 5 parts by weight of aspartic acid.
상기 미네랄이 황산 마그네슘, 글루콘산 칼슘, 젖산 칼슘, 구연산 칼륨, 산화아연, 니코틴산 아미드, 판토텐산 칼슘 및 엽산의 혼합물인 것을 특징으로 하는, 식품 조성물.The method according to claim 1,
Wherein the mineral is a mixture of magnesium sulfate, calcium gluconate, calcium lactate, potassium citrate, zinc oxide, nicotinate amide, calcium pantothenate and folic acid.
상기 미네랄이 WPH 분말 100 중량부를 기준으로, 황산 마그네슘 1 내지 5중량부, 글루콘산 칼슘 1 내지 3중량부, 젖산 칼슘 1 내지 3중량부, 구연산 칼륨 1 내지 5중량부, 산화아연 2 내지 4중량부, 니코틴산 아미드 1 내지 2중량부, 판토텐산 칼슘 0.5 내지 1중량부 및 엽산 0.01 내지 0.05중량부를 포함하는 것을 특징으로 하는, 식품 조성물.6. The method of claim 5,
1 to 5 parts by weight of magnesium sulfate, 1 to 3 parts by weight of calcium gluconate, 1 to 3 parts by weight of calcium lactate, 1 to 5 parts by weight of potassium citrate, and 2 to 4 parts by weight of zinc oxide, based on 100 parts by weight of the WPH powder, 1 to 2 parts by weight of niacinamide, 0.5 to 1 part by weight of calcium pantothenate and 0.01 to 0.05 part by weight of folic acid.
상기 비타민이 비타민 B2, 비타민 B6 염산염, 비타민 B1 염산염 및 비타민 B12의 혼합물인 것을 특징으로 하는, 식품 조성물.The method according to claim 1,
Wherein the vitamin is a mixture of vitamin B2, vitamin B6 hydrochloride, vitamin B1 hydrochloride and vitamin B12.
상기 비타민이 WPH 분말 100 중량부를 기준으로, 비타민 B2 0.02 내지 0.3중량부, 비타민 B6 염산염 0.03 내지 0.3중량부, 비타민 B1 염산염 0.023 내지 0.3중량부 및 비타민 B12 0.015 내지 0.2중량부를 포함하는 것을 특징으로 하는, 식품 조성물.8. The method of claim 7,
Wherein the vitamin comprises 0.02 to 0.3 parts by weight of vitamin B2, 0.03 to 0.3 part by weight of vitamin B6 hydrochloride, 0.023 to 0.3 part by weight of vitamin B1 hydrochloride and 0.015 to 0.2 part by weight of vitamin B12 based on 100 parts by weight of WPH powder , Food composition.
상기 식품 조성물이 식물 추출물, 감미제, 향미제, 안정제, 과즙, 식이섬유, 고결 방지제 및 이의 조합으로 이루어진 군에서 선택되는 식품학적으로 허용 가능한 첨가제를 더 포함하는 것을 특징으로 하는, 식품 조성물.The method according to claim 1,
Wherein the food composition further comprises a pharmaceutically acceptable additive selected from the group consisting of plant extracts, sweeteners, flavors, stabilizers, juices, dietary fiber, anti-caking agents and combinations thereof.
상기 식품학적으로 허용 가능한 첨가제가 10% 과라나 추출물, 아스파탐, 에리스리톨, 구아검, 레몬향 분말, 사과향 분말, 베타 싸이클로덱스트린, 레몬 과즙 분말, 치커리 식이섬유 및 이산화규소인 것을 특징으로 하는, 식품 조성물.10. The method of claim 9,
Wherein the food acceptable additive is 10% guarana extract, aspartame, erythritol, guar gum, lemon flavor powder, apple fruit powder, beta cyclodextrin, lemon juice powder, chicory dietary fiber and silicon dioxide.
상기 식품학적으로 허용 가능한 첨가제가 WPH 분말 100 중량부를 기준으로, 10% 과라나 추출물 3 내지 6중량부; 아스파탐 1 내지 5중량부; 에리스리톨 3 내지 8중량부; 구아검 3 내지 7중량부; 레몬향 분말 5 내지 8중량부; 사과향 분말 5 내지 8중량부; 베타 싸이클로덱스트린 3 내지 7중량부; 레몬 과즙 분말 14 내지 19중량부; 치커리 식이섬유 14 내지 19중량부; 및 이산화규소 0.8 내지 1.1중량부를 포함하는 것을 특징으로 하는, 식품 조성물.11. The method of claim 10,
Wherein said pharmaceutically acceptable excipient comprises, based on 100 parts by weight of WPH powder, from 3 to 6 parts by weight of 10% guarana extract; 1 to 5 parts by weight of aspartame; 3 to 8 parts by weight erythritol; 3 to 7 parts by weight of guar gum; 5 to 8 parts by weight of lemon fragrant powder; 5 to 8 parts by weight of an apple fruit powder; 3 to 7 parts by weight of betacyclodextrin; 14 to 19 parts by weight of lemon juice powder; 14 to 19 parts by weight of Chicory dietary fiber; And 0.8 to 1.1 parts by weight of silicon dioxide.
상기 조성물이 WPH 분말 100 중량부를 기준으로, 대두 펩타이드 32 내지 34중량부; 난백 분말 9 내지 11중량부; 아미노산 26 내지 28중량부; 미네랄(무기영양소) 11 내지 13중량부; 비타민 2 내지 4중량부; 팔라티노스 12 내지 14중량부; 무수구연산 27 내지 29중량부; 결정 과당 21 내지 23중량부; 함수 결정 포도당 12 내지 14중량부; 10% 과라나 추출물 4 내지 5중량부; 아스파탐 3 내지 4중량부; 에리스리톨 5 내지 7중량부; 구아검 4 내지 5중량부; 레몬향 분말 6 내지 7중량부; 사과향 분말 6 내지 7중량부; 베타 싸이클로덱스트린 4 내지 6중량부; 레몬 과즙 분말 15 내지 17중량부; 치커리 식이섬유 15 내지 17중량부; 및 이산화규소 0.8 내지 1.1중량부를 포함하는 것을 특징으로 하는, 식품 조성물.The method according to claim 1,
Said composition comprising, based on 100 parts by weight of WPH powder, 32 to 34 parts by weight of a soybean peptide; 9 to 11 parts by weight of egg white powder; 26 to 28 parts by weight of amino acids; 11 to 13 parts by weight of minerals (inorganic nutrients); 2 to 4 parts by weight of vitamins; 12 to 14 parts by weight of palatinose; 27 to 29 parts by weight of anhydrous citric acid; 21 to 23 parts by weight of crystalline fructose; 12 to 14 parts by weight of hydrous crystalline glucose; 4 to 5 parts by weight of 10% guarana extract; 3 to 4 parts by weight of aspartame; 5 to 7 parts by weight of erythritol; 4 to 5 parts by weight of guar gum; 6 to 7 parts by weight of lemon fragrant powder; 6 to 7 parts by weight of an apple fruit powder; 4 to 6 parts by weight of betacyclodextrin; 15 to 17 parts by weight of lemon juice powder; 15 to 17 parts by weight of Chicory dietary fiber; And 0.8 to 1.1 parts by weight of silicon dioxide.
상기 식품이 과립, 정제, 캡슐, 액상(음료), 파우더, 겔(젤) 또는 분말 형태인 것을 특징으로 하는, 식품.14. The method of claim 13,
Wherein the food is in the form of a granule, a tablet, a capsule, a liquid (beverage), a powder, a gel (gel), or a powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20130047344A KR20140129439A (en) | 2013-04-29 | 2013-04-29 | Food composition for relieving muscle fatigue after exercise |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20130047344A KR20140129439A (en) | 2013-04-29 | 2013-04-29 | Food composition for relieving muscle fatigue after exercise |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20140129439A true KR20140129439A (en) | 2014-11-07 |
Family
ID=52454710
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR20130047344A KR20140129439A (en) | 2013-04-29 | 2013-04-29 | Food composition for relieving muscle fatigue after exercise |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20140129439A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020020450A1 (en) * | 2018-07-25 | 2020-01-30 | Givaudan Sa | Citrus flavour compositions, their use and method of improving organoleptic properties |
| KR102517807B1 (en) * | 2022-07-14 | 2023-04-05 | 코리아콜라겐(주) | Drinking powder composition for boosting body-energy and Drinking powder for boosting body-energy containing the same |
-
2013
- 2013-04-29 KR KR20130047344A patent/KR20140129439A/en not_active Application Discontinuation
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020020450A1 (en) * | 2018-07-25 | 2020-01-30 | Givaudan Sa | Citrus flavour compositions, their use and method of improving organoleptic properties |
| KR102517807B1 (en) * | 2022-07-14 | 2023-04-05 | 코리아콜라겐(주) | Drinking powder composition for boosting body-energy and Drinking powder for boosting body-energy containing the same |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6051236A (en) | Composition for optimizing muscle performance during exercise | |
| US6903136B2 (en) | Food supplements containing 4-hydroxyisoleucine and creatine | |
| US20050276839A1 (en) | Appetite satiation and hydration beverage | |
| JP6346558B2 (en) | Food and drink with excellent moisture absorption | |
| CN102283294A (en) | Sports beverage containing whey protein and preparation method thereof | |
| EP3355989A1 (en) | Composition for improved performance | |
| KR101863328B1 (en) | Food composition for enhancing exercise performance to acute and endurance exercise | |
| JP2013542924A (en) | Method for reducing blood lactate concentration | |
| WO2006118090A1 (en) | Water-containing food | |
| CN108606269B (en) | Sports nutritional supplement and preparation method thereof | |
| EP3977868A1 (en) | High-energy food supplement based on inverted sugars and ergogenic products for use in physical activity and method for producing same | |
| US20060188627A1 (en) | Isomaltulose or trehalose containing comestibles for sustained carbohydrate energy release and increased fat oxidation | |
| JP6870327B2 (en) | Jelly containing free amino acids or salts thereof | |
| JP2012246241A (en) | Aspartate-containing oral composition | |
| KR20140129439A (en) | Food composition for relieving muscle fatigue after exercise | |
| KR101700942B1 (en) | Sports beverage compositions | |
| US20160082061A1 (en) | Nutritional composition and method of manufacture | |
| US20110263697A1 (en) | Methods of Reducing Oxidative Modification of a Muscle Cell Protein | |
| JP2014030422A (en) | Beverage | |
| CN108124416B (en) | Long-shelf-life original-taste milk-containing beverage and preparation method thereof | |
| JPH0549444A (en) | Food for improvement of stamina | |
| JP2013066440A (en) | Beverage composition | |
| JP2010095474A (en) | Calcium absorption-promoting composition and calcium absorption-promoting food and drink | |
| CN118077889A (en) | Exercise endurance supplement containing beta-alanine | |
| KR20240145579A (en) | Composition for improving muscular function comprising fermented whey protein as effective component |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |